Introduction
Renal artery stenosis can lead to secondary hypertension and renal failure, and is caused by atherosclerosis in approximately 90% of the patients. 1, 2 The optimal treatment for patients with atherosclerotic renal artery stenosis and hypertension without chronic renal insufficiency is still unclear. Three randomized trials comparing balloon angioplasty with conservative treatment showed that blood pressure was not significantly better controlled after balloon angioplasty, although less antihypertensive medication was needed. [3] [4] [5] A meta-analysis combining these trials also did not show a clear benefit of angioplasty. 6 Furthermore, it is unclear whether invasive treatment offers an advantage over conservative treatment for prevention of renal failure in patients with stable renal function. 7, 8 In a randomized trial comparing angioplasty with additional stent placement and angioplasty alone, additional stent placement did not improve the clinical outcomes after 6 months despite a higher rate of technical success and a lower rate of restenosis. 9 Since invasive treatment is costly and not without risk, 10, 11 one may propose that it is sensible to treat nonazotemic patients with atherosclerotic renal artery stenosis and hypertension by aggressive drug therapy and to perform an intervention only if the hypertension persists or if the renal function deteriorates. Some subgroups of patients may benefit from immediate intervention; however, either because they are likely to have a favourable response to intervention or because they are at risk for rapid deterioration of renal function. We explored this assumption by studying the changes in blood pressure and renal function after 1 year of treatment in patients who were randomized between immediate balloon angioplasty and drug therapy followed by angioplasty if hypertension persisted or renal function deteriorated in the DRASTIC study. 5 
Patients and methods

Study population
Patients participated in a prospective randomized study that was designed to identify patients with renal artery stenosis and to evaluate their treatment (the DRASTIC study). 12 Patients had been referred because of difficult-to-treat hypertension associated with normal or mildly impaired renal function (defined as a serum creatinine concentration of 200 mmol/l (2.3 mg/dl) or less). The patients in the present analysis were from the therapeutic phase of the study, which was described elsewhere in detail. 5 In total, 106 patients with atherosclerotic renal artery stenosis of 50% of lumen diameter or more according to arterial digital subtraction angiography were randomized between two treatment strategies: immediate balloon angioplasty (PTRA, n ¼ 56) and drug therapy followed by balloon angioplasty after 3 months, if needed (Med-PTRA, n ¼ 50). In accordance with the study protocol, 22 of the 50 patients in the Med-PTRA group underwent angioplasty after 3 months because of persistent hypertension (diastolic blood pressure of 95 mmHg or higher) despite treatment with three or more drugs (n ¼ 14), or because of progressive renal failure (as indicated by an increase in the serum creatinine concentration of 20 mmol/l (0.23 mg/dl) or more, or worsening of the time-activity curve on renal scintigraphy; n ¼ 8). All patients gave written informed consent. Blood pressure and renal function after 1 year did not differ significantly between the randomized groups. 5 
Clinical data
In the present study, the clinical outcomes were change in diastolic blood pressure and change in creatinine clearance from baseline (before randomization) to 1 year. The baseline blood pressure was defined as the average of office blood pressure readings at three consecutive visits, and the blood pressure after 1 year was defined as the average of all available office blood pressure readings measured between 9 and 12 months after randomization (average two visits, range 1-4 visits). At each visit, the blood pressure was measured three times using a standard sphygmomanometer in sitting position after 5 min rest. The creatinine clearance at baseline and after 1 year were calculated according to the Cockcroft formula. 13 Data on diastolic blood pressure and creatinine clearance after 1 year were available for 103 and 102 patients, respectively.
As a rule, the results of subgroup analyses should be interpreted with caution. 14, 15 To improve the credibility of our analyses, a limited number of subgroups were selected on the basis of clinical plausibility. We studied three subgroups of patients with a supposedly good response to intervention: those with positive captopril-renin challenge test 16, 17 (1-h plasma renin X50 mU/ml; this cutoff represents the optimal value for identifying renal artery stenosis in our study group), 18 those with abnormal renogram after stimulation with captopril, 19 and those with recently developed hypertension (within the last 2 years). 20, 21 Two subgroups of patients with a supposed risk for rapid disease progression were studied: those with bilateral stenosis (X50% of lumen diameter on both sides), and those with severe stenosis (X80% of lumen diameter). 22, 23 Subgroup data were available for all patients except for the captopril-renin challenge test and on captopril renography. These tests were not performed in 28 patients and in three patients, respectively, for logistic reasons.
Statistical analysis
We applied analysis of covariance to study the change in diastolic blood pressure in the subgroup of patients with a positive captopril-renin challenge test. The blood pressure at baseline was included as a covariate in the analysis to adjust for its correlation with the blood pressure level after 1 year. 24 Mathematically, the analysis of treatment effect according to change in outcome with the baseline value as covariate is equivalent to the more standard analysis of outcome with the baseline value as covariate. To study whether the difference, if any, in the effect of the treatment strategies on blood pressure was similar for patients with a positive and a negative captopril-renin challenge test, an interaction term of treatment strategy (PTRA or Med-PTRA) with captopril-renin challenge test (positive or negative) was tested in an analysis of covariance using all patients. 15 Again, diastolic blood pressure at baseline was included as a covariate. Similar analyses were performed to study the effect of treatment on diastolic blood pressure for the other patient subgroups, and to study the effect of treatment on renal function in all patient subgroups. In the latter analyses, the change in creatinine clearance from baseline to 1 year was used as the dependent variable (outcome), and the creatinine clearance at baseline was included as a covariate. P-values o0.05 were considered statistically significant.
Results
The patients in the PTRA group and in the Med-PTRA group did not differ with respect to sex, age, blood pressure, number of drugs, and creatinine clearance at baseline (Table 1) . Also, the proportions Immediate intervention in renal artery stenosis P Krijnen et al of patients with positive captopril-renin challenge test, with an abnormal renogram, with recently developed hypertension, with bilateral stenosis, and with severe stenosis were similar in these groups. The distribution of these characteristics was similar for the 66 patients with complete data (data not shown).
Baseline levels and outcomes after 3 months
The diastolic blood pressure levels at baseline of patients with a positive captopril-renin challenge test, with an abnormal renogram, with recently developed hypertension, with bilateral stenosis, or with severe stenosis were fairly comparable to those of patients without the respective characteristic (Table 2) . Patients with bilateral stenosis had a lower baseline creatinine clearance on average than those with unilateral stenosis (Table 3 ; Po0.0001). Also, the average baseline creatinine clearance was lower in patients with severe stenosis compared to patients with moderate stenosis (P ¼ 0.02). The baseline creatinine clearance levels were equal for the patients in the other subgroups. Three months after randomization, the improvement in blood pressure (Table 2 ) and in creatinine clearance (Table 3) tended to be larger in the PTRA group. At that point in time, all patients in the Med-PTRA group had been treated by drug therapy only. In accordance with the study protocol, a number of patients in the Med-PTRA group received angioplasty after 3 months because of persistent hypertension or deterioration of renal function: 13/26 (50%) and 5/7 (71%) of patients with positive and negative captoprilrenin challenge test, respectively; 14/32 (44%) and 7/17 (41%) of patients with an abnormal and a normal renogram, respectively; 7/17 (41%) and 15/33 (46%) of patients with recent and longer existing hypertension, respectively; 6/11 (55%) and 16/39 (41%) of patients with bilateral and unilateral stenosis, respectively; and 15/26 (58%) and 7/24 (29%) of patients with severe and moderate stenosis, respectively. These differences were not statistically significant except for the difference between the patients with severe stenosis and those with moderate stenosis (P ¼ 0.04). Immediate intervention in renal artery stenosis P Krijnen et al
Outcomes after 1 year
Blood pressure After 1 year, the diastolic blood pressure had decreased on average in both treatment groups. The drop in blood pressure level in the PTRA group seemed somewhat larger than in the Med-PTRA group: 11.6 7 11.3 mmHg and 7.2 7 9.6 mmHg (mean 7 s.d.). This difference was not statistically significant after adjustment for blood pressure at baseline, however (P ¼ 0.06). The apparent benefit in the PTRA group was largest in the patients with bilateral stenosis (Table 2 ): 12.2 7 11.3 mmHg for patients in the PTRA group and 4.0 7 8.5 mmHg for patients in the Med-PTRA group (P ¼ 0.07). The benefit of PTRA over Med-PTRA within this subgroup seemed higher than for patients with unilateral stenosis, but was not statistically significant (interaction, P ¼ 0.46). For the other subgroups (patients with a positive captopril-renin challenge test, patients with an abnormal renogram, patients with recent hypertension, and patients with severe stenosis), the differences between PTRA and Med-PTRA were smaller and not statistically significant.
Renal function
After 1 year, the creatinine clearance had somewhat increased on average in both treatment groups: 2.3 7 15.4 and 3.4 7 13.7 ml/min. This difference was not statistically significant after adjustment for the creatinine clearance at baseline (P ¼ 0.51). In all subgroups but one, the average creatinine clearance was stable or had increased after 1 year (Table 3 ). The creatinine clearance of patients with bilateral stenosis, who were randomized for Med-PTRA, had decreased by À4.2 7 13.5 ml/min. This occurred despite the fact that six of these 11 patients underwent angioplasty after 3 months of follow-up. On the other hand, the creatinine clearance of the patients with bilateral stenosis, who were randomized for PTRA, had improved substantially after 1 year by +10.0 7 15.7 ml/min (P ¼ 0.03). For patients with unilateral stenosis, the average creatinine clearance had improved somewhat in both treatment groups (+1.3 7 12.5 ml/min in the angioplasty group and +4.3 7 15.5 ml/min in the drug-therapy group). The difference in treatment effect on renal function between the patients with bilateral stenosis and those with unilateral stenosis was statistically significant (interaction term; P ¼ 0.007). For none of the other subgroups, a clear difference between the PTRA group and the Med-PTRA group was found.
Discussion
Our main finding was that patients with atherosclerotic bilateral stenosis had an evident benefit of immediate intervention compared to drug therapy followed by intervention after 3 months, if needed. These patients had a normal or mildly impaired renal function at study entry. After 1 year of follow-up, their renal function had improved if intervention had taken place immediately after the diagnosis, whereas it had deteriorated if intervention had been performed after 3 months in case of persistent hypertension or a decline in renal function. This finding is consistent with the studies reporting that patients with bilateral stenosis have an increased risk of progressive renal dysfunction. 22, 23 The patients with bilateral stenosis also seemed to benefit most from immediate intervention with regard to blood pressure control.
We did not find any other subgroup with a clear benefit of immediate intervention, either with regard to blood pressure control or with regard to preservation of renal function. A serious limitation of our study, however, was the lack of statistical power for detecting small differences in treatment effects per subgroup. 15 Our study should therefore be regarded as exploratory. Nevertheless, this is the only study reporting on treatment effects in these subgroups of patients with atherosclerotic renal artery stenosis so far. Another prospective study to confirm these results may not be feasible, given the large numbers of patients needed per subgroup to reach statistical significance.
The results of the treatment strategies with regard to preservation of renal function may have been influenced in a number of ways. First, the assessment of renal function with the creatinine clearance according to the Cockcroft formula was rather crude. Unfortunately, no other data were available by which the renal function could have been assessed more accurately. Also, the use of ACE inhibitors, AT1 antagonists, and diuretics could have affected the renal function, especially in patients with bilateral stenosis. Whereas AT1 antagonists, were not used at all, ACE inhibitors and diuretics were used by comparable proportions of the patients in the treatment groups and were used only in low dosages. Patients with bilateral disease benefitted by immediate intervention whereas they used ACE inhibitors twice as often as the patients with bilateral disease who were allocated to medication.
A benefit of immediate intervention for preservation of renal function may have been hidden for the subgroups of patients with a positive captoprilrenin challenge test, with an abnormal renogram, and with recently developed hypertension. The patients with these characteristics, who were allocated to initial medication, had a relatively worse renal function at baseline, and, consequently, could have gained more from treatment than the patients who were allocated to immediate intervention. However, the actual benefit in renal function after 1 year seemed larger in the patients who received medication only in the subgroup with recent hypertension.
Another limitation was that the treatment strategies in this study did not include renal artery stent placement. Stent placement is superior to angioplasty alone on theoretical grounds. Until now, only one randomized study was published that compared stent placement with angioplasty alone. 9 Although this study reported superior vessel patency and a lower restenosis rate after stent placement, the clinical outcomes after stent placement were similar to those after angioplasty alone. The follow-up in this study was limited to 6 months, however. Based on the available evidence of this randomized study, we suppose that our conclusions would have been similar if additional stent placement would have been included in both treatment arms.
Percutaneous intervention can successfully control blood pressure in patients with renovascular (ie, renin-dependent) hypertension. 25 Reviews of medical therapy for renovascular hypertension have shown, however, that modern antihypertensive drugs, such as angiotensin converting enzyme (ACE) inhibitors and calcium channel blockers, can achieve adequate blood pressure control in a large proportion of patients with renovascular hypertension. 26 Renovascular hypertension is supposed to be more likely in patients in whom the plasma renin activity is increased after stimulation with captopril (captopril-renin challenge test), 16 in patients with an abnormal renogram after stimulation with captopril, 19 and in patients with recently developed hypertension. 20, 21 In these subgroups, immediate intervention did not have an apparent benefit over restricting intervention to those patients in whom hypertension persisted or renal function declined after 3 months of drug therapy. This benefit, if any, is small and probably does not outweigh the risks of complications and cost of intervention for patients in whom blood pressure can be controlled medically.
Successful intervention may preserve or even restore the renal function in patients with atherosclerotic renal artery stenosis whose renal function is already deteriorating. [27] [28] [29] [30] [31] For patients with a normal or mildly impaired renal function, however, it is unclear if and when intervention should be performed to prevent progressive renal failure, because the rate of progressive narrowing of the renal artery and the associated rate of progressive renal failure is generally slow. 32 Our study shows that intervention should not be postponed in patients with bilateral stenosis, even if their renal function is not impaired as yet. This result is in agreement with a prospective study on disease progression, showing that renal survival was lowest in patients with bilateral stenosis, especially in case of an occluded renal artery on one side. 22 Severe unilateral stenosis, on the other hand, did not seem to justify immediate intervention in our study. Although severe stenoses are more likely to progress than less advanced lesions, 32 renal insufficiency develops mainly in patients in whom the entire renal mass is affected. 26 Even in patients with severe stenosis, bilateral disease is present in a minority of cases (in our sample, 34%). Stenosis could be expected to develop in the contralateral kidney, however, although this process is unpredictable and may take a long time. 33 In conclusion, intervention should be performed immediately in hypertensive patients with atherosclerotic renal artery stenosis and a normal or mildly impaired renal function if bilateral disease is diagnosed. In the remaining patients, aggressive drug therapy followed by intervention in a selection of patients after 3 months is a sensible treatment strategy. In this way, unnecessary interventions can be avoided in a considerable number of patients. Clinicians should be wary of the disease progression, however, especially in patients with severe unilateral disease.
